Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04816214
Title Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Capmatinib + Osimertinib

Age Groups: adult | senior
Covered Countries

Facility Status City State Zip Country Details
Novartis Investigative Site Kashiwa Chiba 277 8577 Japan Details
Novartis Investigative Site Sunto Gun Shizuoka 411 8777 Japan Details
Novartis Investigative Site Seoul 05505 Korea, Republic of Details
Novartis Investigative Site Singapore 169610 Singapore Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field